Brian B Latario

20060188885, Aug 24, 2006

Apr 16, 2004

10/553520

Dale Bodian - Whippany NJ, US
Sherif Daouti - Hasbrouck Heights NJ, US
Chandrika Kumar - Acton MA, US
Brian Latario - Groton MA, US
Joseph Quintavalla - New Providence NJ, US

C12Q 1/68

435006000

High-throughput functional screening assays are provided that identify genes and gene products that are associated with the pathogenesis of osteoarthritis (OA) in chondrocytes. In addition, genes and gene products identified by such functional assays are also provided. The genes and gene products provided herein are useful inter alia for diagnosing OA in individuals and as drug targets for identifying drugs to treat OA.

20070142273, Jun 21, 2007

Apr 16, 2004

10/553730

Sherif Daouti - Hasbrouck Heights NJ, US
Chandrika Kumar - Acton MA, US
Brian Latario - Groton MA, US

A61K 38/17
C12Q 1/68
G01N 33/567

514012000, 435007200, 435006000

The invention discloses that members of a subfamily of receptor tyrosine kinases comprising TYRO3, Axl, cMer and ligands thereof, such as GAS6 are suitable targets for the development of new therapeutics to treat, prevent or ameliorate OA. The invention also relates to methods to treat and/or ameliorate OA and pharmaceutical compositions therefore comprising modulators with inhibitory effect on the expression or activity of members of this subfamily of receptor tyrosine and related ligands. The invention also relates to a method to identify compounds with therapeutic usefulness to treat OA, comprising identifying compounds that can, e.g., inhibit activity and/or expression of these polypeptides.

20090136506, May 28, 2009

Oct 2, 2006

12/089005

Mark Bittinger - West Roxbury MA, US
Christine Chow - Boston MA, US
Danilo Guerini - Reinach, CH
Mark Aron Labow - Lexington MA, US
Brian Jude Latario - Groton MA, US
Zhao-Hui Xiong - Winchester MA, US

A61K 39/395
C07K 14/00
C07K 16/00
C07H 21/00
A61K 31/7088
A61P 25/00
G01N 33/53
C12N 15/74
C12N 5/10
C12P 21/00

4241391, 530324, 5303879, 536 2353, 4353201, 435325, 435 691, 514 44, 435 71

The invention discloses the first known function and biological activity of the hypothetical protein MGC14327, now designated cMAC, which is herein identified as an important controller of T-cell activation. It is contemplated herein that cMAC is a suitable drug target for the development of new therapeutics to treat cMAC-associated disorders. The invention relates to methods to treat said pathological conditions and to pharmaceutical compositions therefore. The pharmaceutical compositions comprise modulators with inhibitory or agonist effect on cMAC protein activity and/or cMAC gene expression. The invention also relates to methods to identify compounds with therapeutic usefulness to treat said pathological conditions, comprising identifying compounds that can inhibit or agonize cMAC protein activity and/or cMAC gene expression.

20060067938, Mar 30, 2006

Oct 25, 2002

10/491798

Sherif Daouti - Hasbrouck Heights NJ, US
Chanrika Kumar - Maynard MA, US
Brian Latario - Groton MA, US

A61K 31/5377
A61K 39/395

424146100, 514232500

The invention discloses PI3K, PKB, IL-1, and OSM as suitable targets for the development of new therapeutics to treat, prevent or ameliorate osteoarthritis (OA). The invention relates to methods to treat, prevent or ameliorate OA and pharmaceutical compositions therefor comprising substances with inhibitory effects on PI3K and/or PKB enzyme activity and/or gene expression and IL-1 and/or OSM activity or gene expression. The invention also relates to a method to identify compounds with therapeutic usefulness to treat OA, comprising identifying compounds that can effect PI3K and/or PKB activity and/or gene expression and/or IL-1 or OSM activation of PI3K and/or PKB activity and/or gene expression which leads to downregulation of AGG-1 and/or COL-3 and thus prevent, treat or ameliorate OA in vivo.